Yuxi Walvax Biotechnology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary, Public
- Established
- 2001-01-16
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.walvax.com
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
Phase 3
Active, not recruiting
- Conditions
- Pneumococcal Disease, Invasive
- Interventions
- Biological: Pfizer PCV13Biological: Walvax PCV13-TT
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT05934890
- Locations
- 🇮🇩
Ilmu Kesehatan anak FKUI RSCM, Jakarta Pusat, Jakarta, Indonesia
🇮🇩RSUP Prof. Dr. I.G.N.G Ngoerah, Denpasar, Bali, Indonesia
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
- Conditions
- COVID-19
- Interventions
- Biological: ComirnatyBiological: RQ3013
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05396573
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Phase 1
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: ComirnatyBiological: RQ3013
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05394012
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Phase 3
- Conditions
- SARS-CoV-2COVID-19
- Interventions
- Biological: SARS-CoV-2 mRNA VaccineBiological: Placebo
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 28000
- Registration Number
- NCT04847102
- Locations
- 🇲🇽
Centro de Investigación y Avances Médicos Especializados (CIAME), Cancun, Mexico
🇲🇽Oaxaca site management organization (OSMO), Oaxaca, Mexico
🇮🇩Puskesmas Duren Sawit, Jakarta, Indonesia
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Phase 4
Completed
- Conditions
- Neisseria Meningitides Meningitis
- Interventions
- Biological: Sanofi Pasteur Menactra® vaccineBiological: Yuxi Walvax MPV ACYW® vaccine
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT04450498
- Locations
- 🇲🇱
Centre pour le Développement des Vaccins du Mali, Bamako, Mali
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
Phase 1
Completed
- Conditions
- Meningococcal Infections
- Interventions
- Biological: Meningococcal Group ACYW135 Conjugate Vaccine
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04236960
- Locations
- 🇨🇳
Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
Phase 3
Completed
- Conditions
- Diseases Caused by Streptococcus Pneumoniae Serotypes
- Interventions
- Biological: 7-valent pneumococcal conjugate vaccineBiological: 13-valent pneumococcal polysaccharide conjugate vaccine
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 2760
- Registration Number
- NCT02736240
Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Phase 3
Completed
- Conditions
- Pneumococcal Infectious Diseases
- Interventions
- Biological: vaccination PNEUMOVAX 23Biological: vaccination PPV23
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Walvax Biotechnology Co., Ltd.
- Target Recruit Count
- 1660
- Registration Number
- NCT02285036
- Locations
- 🇨🇳
Guangxi Provincial Center for Diseases Control and Prevention, Nanning, Guangxi, China
© Copyright 2025. All Rights Reserved by MedPath